SPHINX31

Catalog No.S8810 Batch:S881001

Print

Technical Data

Formula

C27H24F3N5O2
Molecular Weight 507.51 CAS No. 1818389-84-2
Solubility (25°C)* In vitro DMSO 25 mg/mL (49.26 mM)
Ethanol 13 mg/mL (25.61 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SPHINX31 is a SRPK1 inhibiror with an IC50 of 5.9 nM with highly selectivity for SRPK1 over SRPK2 (50-fold) and CLK1 (100-fold).
Targets
SRPK1 [1]
(Cell-free assay)
5.9 nM
In vitro

Kinase assays showed that SPHINX31 is a type 1 kinase inhibitor (ATP competitive). SPHINX31 treatment results in inhibition of SRSF1 phosphorylation at 300 nM in PC3 prostate cancer cells. Metabolic stability in mouse liver microsomes shows that SPHINX31 had medium clearance with a T1/2 of 95.79 min[1]. Inhibition of SRPK1 using SPHINX31 leads to cell cycle arrest and leukemic cell differentiation[2].
In vivo

SPHINX31 could penetrate into the eye. SPHINX31 exerts a dose dependent inhibition of choroidal neovascularisation in mouse model. SPHINX31 inhibits blood vessel growth and macrophage infiltration[1]. SPHINX31 treatment prolongs survival of immunocompromised mice transplanted with MLL-rearranged AML cells[2].

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    THP1 cells

  • Concentrations

    3 µM

  • Incubation Time

    24 h

  • Method

    --
Animal Study:

[2]
  • Animal Models

    DBA2J mice

  • Dosages

    0.8 mg/kg

  • Administration

    i.p.

Selleck's SPHINX31 has been cited by 2 publications

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia [ Leukemia, 2023, 37(8):1649-1659] PubMed: 37422594
SRPKIN-1 as an inhibitor against hepatitis B virus blocking the viral particle formation and the early step of the viral infection [ Antiviral Res, 2023, 10.1016/j.antiviral.2023.105756] PubMed: 37992764

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.